PMID- 10430223
OWN - NLM
STAT- MEDLINE
DCOM- 19990824
LR  - 20200930
IS  - 1525-4135 (Print)
IS  - 1525-4135 (Linking)
VI  - 21 Suppl 1
DP  - 1999 Aug 1
TI  - Developing immunotherapeutic strategies for the control of Epstein-Barr 
      virus-associated malignancies.
PG  - S80-3
AB  - Epstein-Barr virus (EBV) infection is associated with various physical human 
      malignancies. The potential for immunotherapeutic treatment by cytotoxic T cells 
      (CTL) depends on the degree of EBV-antigen expression, with the best prospect 
      revolving around the immunoblastic lymphomas of organ transplant patients in 
      which adoptive transfer of in vitro reactivated CTL has already been demonstrated 
      to be effective. Opportunities for effective immunotherapy in the treatment of 
      nasopharyngeal carcinoma (NPC) is reduced because the available targets are 
      limited to relatively nonimmunogenic proteins. However, analysis of NPC cells has 
      revealed normal expression of the major histocompatibility complex (MHC)-encoded 
      peptide transporters TAP-1 and TAP-2, together with high levels of human 
      leukocyte antigen (HLA) class I alleles on the cell surface. Burkitt's lymphoma 
      (BL) displays downregulated expression of MHC class I and TAP-1 and TAP-2 
      proteins, whereas viral antigen expression is limited to a protein incapable of 
      processing class I CTL epitopes. It therefore seems likely that effective 
      treatment of BL will revolve around protocols designed to reverse its 
      undifferentiated phenotype.
FAU - Moss, D J
AU  - Moss DJ
AD  - Epstein-Barr Virus Unit, University of Queensland and the Queensland Institute of 
      Medical Research, Brisbane, Australia. denisM@qimr.edu.au
FAU - Khanna, R
AU  - Khanna R
FAU - Sherritt, M
AU  - Sherritt M
FAU - Elliott, S L
AU  - Elliott SL
FAU - Burrows, S R
AU  - Burrows SR
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - J Acquir Immune Defic Syndr
JT  - Journal of acquired immune deficiency syndromes (1999)
JID - 100892005
RN  - 0 (Antigens, Viral)
SB  - IM
MH  - AIDS-Related Opportunistic Infections/therapy/virology
MH  - Antigens, Viral/immunology
MH  - Burkitt Lymphoma/therapy/virology
MH  - Herpesviridae Infections/*therapy
MH  - *Herpesvirus 4, Human/immunology
MH  - Humans
MH  - *Immunotherapy
MH  - Lymphoma, B-Cell/therapy/virology
MH  - Nasopharyngeal Neoplasms/therapy/virology
MH  - T-Lymphocytes, Cytotoxic/immunology
MH  - Tumor Virus Infections/*therapy
RF  - 27
EDAT- 1999/08/03 00:00
MHDA- 1999/08/03 00:01
CRDT- 1999/08/03 00:00
PHST- 1999/08/03 00:00 [pubmed]
PHST- 1999/08/03 00:01 [medline]
PHST- 1999/08/03 00:00 [entrez]
PST - ppublish
SO  - J Acquir Immune Defic Syndr. 1999 Aug 1;21 Suppl 1:S80-3.